JPH09500111A - イミノジ酢酸エステル結合に基づく選択的に開裂可能なリンカー - Google Patents
イミノジ酢酸エステル結合に基づく選択的に開裂可能なリンカーInfo
- Publication number
- JPH09500111A JPH09500111A JP7503047A JP50304795A JPH09500111A JP H09500111 A JPH09500111 A JP H09500111A JP 7503047 A JP7503047 A JP 7503047A JP 50304795 A JP50304795 A JP 50304795A JP H09500111 A JPH09500111 A JP H09500111A
- Authority
- JP
- Japan
- Prior art keywords
- solid phase
- linker
- phase carrier
- peptide
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 196
- 239000007790 solid phase Substances 0.000 claims abstract description 74
- 239000007787 solid Substances 0.000 claims abstract description 58
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 53
- 230000007017 scission Effects 0.000 claims abstract description 47
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims abstract description 41
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 35
- 150000002148 esters Chemical class 0.000 claims abstract description 34
- 239000000969 carrier Substances 0.000 claims abstract description 4
- 229920005989 resin Polymers 0.000 claims description 55
- 239000011347 resin Substances 0.000 claims description 55
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 45
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 43
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 230000000269 nucleophilic effect Effects 0.000 claims description 34
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 32
- 239000002253 acid Substances 0.000 claims description 25
- 108010016626 Dipeptides Proteins 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 239000012038 nucleophile Substances 0.000 claims description 21
- -1 polyethylene Polymers 0.000 claims description 20
- 238000012360 testing method Methods 0.000 claims description 18
- 125000006239 protecting group Chemical group 0.000 claims description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 16
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 15
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 11
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- 150000001414 amino alcohols Chemical class 0.000 claims description 5
- WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical compound [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 claims description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 125000003158 alcohol group Chemical group 0.000 claims description 3
- 229960004275 glycolic acid Drugs 0.000 claims description 3
- OWOHLURDBZHNGG-UHFFFAOYSA-N Hexahydropyrrolo[1,2-a]pyrazine-1,4-dione Chemical group O=C1CNC(=O)C2CCCN12 OWOHLURDBZHNGG-UHFFFAOYSA-N 0.000 claims description 2
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical class C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 claims description 2
- 239000012039 electrophile Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 229920006122 polyamide resin Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920005990 polystyrene resin Polymers 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims 4
- TWIRMOOLOHGXFF-UHFFFAOYSA-N 2-[(2-aminoacetyl)-(carboxymethyl)amino]acetic acid Chemical compound NCC(=O)N(CC(O)=O)CC(O)=O TWIRMOOLOHGXFF-UHFFFAOYSA-N 0.000 claims 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 2
- 150000002466 imines Chemical class 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 206010034960 Photophobia Diseases 0.000 claims 1
- 108010093581 aspartyl-proline Proteins 0.000 claims 1
- RIZMRRKBZQXFOY-UHFFFAOYSA-N ethion Chemical compound CCOP(=S)(OCC)SCSP(=S)(OCC)OCC RIZMRRKBZQXFOY-UHFFFAOYSA-N 0.000 claims 1
- 208000013469 light sensitivity Diseases 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 238000007344 nucleophilic reaction Methods 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920013716 polyethylene resin Polymers 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 32
- 238000010647 peptide synthesis reaction Methods 0.000 abstract description 15
- 125000004122 cyclic group Chemical group 0.000 abstract description 14
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract description 6
- MGMNPSAERQZUIM-UHFFFAOYSA-N 2-(hydroxymethyl)benzoic acid Chemical compound OCC1=CC=CC=C1C(O)=O MGMNPSAERQZUIM-UHFFFAOYSA-N 0.000 abstract description 5
- 235000013922 glutamic acid Nutrition 0.000 abstract description 5
- 239000004220 glutamic acid Substances 0.000 abstract description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract description 2
- 235000003704 aspartic acid Nutrition 0.000 abstract description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract description 2
- 125000005647 linker group Chemical group 0.000 description 209
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 102
- 102000004196 processed proteins & peptides Human genes 0.000 description 56
- 239000000243 solution Substances 0.000 description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 55
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 37
- 239000011324 bead Substances 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 31
- 229940024606 amino acid Drugs 0.000 description 31
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 30
- 239000000047 product Substances 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000003556 assay Methods 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 15
- 230000004071 biological effect Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 13
- 238000004809 thin layer chromatography Methods 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 238000010511 deprotection reaction Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 125000003277 amino group Chemical group 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 238000009739 binding Methods 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 9
- 229960004452 methionine Drugs 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 238000007363 ring formation reaction Methods 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 229930182817 methionine Natural products 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 150000008064 anhydrides Chemical class 0.000 description 7
- 238000004166 bioassay Methods 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 239000011877 solvent mixture Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010067902 Peptide Library Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- WWYFPDXEIFBNKE-UHFFFAOYSA-N 4-(hydroxymethyl)benzoic acid Chemical compound OCC1=CC=C(C(O)=O)C=C1 WWYFPDXEIFBNKE-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- 101000614988 Homo sapiens Mediator of RNA polymerase II transcription subunit 12 Proteins 0.000 description 3
- 108010022337 Leucine Enkephalin Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 102100021070 Mediator of RNA polymerase II transcription subunit 12 Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 3
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 3
- 235000008206 alpha-amino acids Nutrition 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000007327 hydrogenolysis reaction Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000007030 peptide scission Effects 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108010070643 prolylglutamic acid Proteins 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 2
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical group CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- QLROSWPKSBORFJ-BQBZGAKWSA-N L-Prolyl-L-glutamic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 QLROSWPKSBORFJ-BQBZGAKWSA-N 0.000 description 2
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 2
- 239000012965 benzophenone Substances 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical group C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- JXGVXCZADZNAMJ-NSHDSACASA-N (2s)-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1=CC=CC=C1 JXGVXCZADZNAMJ-NSHDSACASA-N 0.000 description 1
- PVFCXMDXBIEMQG-JTQLQIEISA-N (2s)-2-(phenylmethoxycarbonylamino)pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 PVFCXMDXBIEMQG-JTQLQIEISA-N 0.000 description 1
- AJDUMMXHVCMISJ-ZDUSSCGKSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxo-5-phenylmethoxypentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC(=O)OCC1=CC=CC=C1 AJDUMMXHVCMISJ-ZDUSSCGKSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- WXYGVKADAIJGHB-ZDUSSCGKSA-N (2s)-3-(1h-indol-2-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C1=CC=C2NC(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CC2=C1 WXYGVKADAIJGHB-ZDUSSCGKSA-N 0.000 description 1
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LINBWYYLPWJQHE-UHFFFAOYSA-N 3-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCC(=O)O)C3=CC=CC=C3C2=C1 LINBWYYLPWJQHE-UHFFFAOYSA-N 0.000 description 1
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 1
- VUTBELPREDJDDH-UHFFFAOYSA-N 4-amino-5-hydroxymethyl-2-methylpyrimidine Chemical compound CC1=NC=C(CO)C(N)=N1 VUTBELPREDJDDH-UHFFFAOYSA-N 0.000 description 1
- XDOLZJYETYVRKV-UHFFFAOYSA-N 7-Aminoheptanoic acid Chemical compound NCCCCCCC(O)=O XDOLZJYETYVRKV-UHFFFAOYSA-N 0.000 description 1
- UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- NIOPEYHPOBWLQO-KBPBESRZSA-N Gly-Trp-Glu Chemical compound NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(O)=O NIOPEYHPOBWLQO-KBPBESRZSA-N 0.000 description 1
- PYFIQROSWQERAS-LBPRGKRZSA-N Gly-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(=O)NCC(O)=O)=CNC2=C1 PYFIQROSWQERAS-LBPRGKRZSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 102400000243 Leu-enkephalin Human genes 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- IDIDJDIHTAOVLG-UHFFFAOYSA-N S-methyl-L-cysteine Natural products CSCC(N)C(O)=O IDIDJDIHTAOVLG-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- UYKREHOKELZSPB-JTQLQIEISA-N Trp-Gly Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(O)=O)=CNC2=C1 UYKREHOKELZSPB-JTQLQIEISA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229920003180 amino resin Polymers 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- DVUFTQLHHHJEMK-UHFFFAOYSA-N aspartyl-alanine Chemical group OC(=O)C(C)NC(=O)C(N)CC(O)=O DVUFTQLHHHJEMK-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical class NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 125000001142 dicarboxylic acid group Chemical group 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-M glutaminate Chemical compound [O-]C(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-M 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000010559 graft polymerization reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000010262 intracellular communication Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960002195 perazine Drugs 0.000 description 1
- SPEXCGKGVJUPGG-UHFFFAOYSA-N phenyl-(2-sulfanylphenyl)methanone Chemical compound SC1=CC=CC=C1C(=O)C1=CC=CC=C1 SPEXCGKGVJUPGG-UHFFFAOYSA-N 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 108010004034 stable plasma protein solution Proteins 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fertilizers (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.イミノジ酢酸および求核性基を含んでなる、試験化合物の固相合成に適する タイプの固相担体であって、1つの酢酸カルボキシル基が固相担体に結合されて いる、上記の固相担体。 2.求核性基が保護基により保護されている、請求項1に記載の固相担体。 3.保護基がFmoc、Boc、Npys、Alloc、Zおよび修飾Z基より成る群から選ばれ る、請求項2に記載の固相担体。 4.求核性基が約6より高いpHでエステル結合と反応し得るアミンまたはイミ ンである、請求項1に記載の固相担体。 5.求核性基が約pH 8.5でエステル結合と反応し得るものである、請求項4に記 載の固相担体。 6.ポリスチレン樹脂、ポリハイプ(polyhipe)樹脂、ポリアミド樹脂、ポリエチ レングリコールでグラフトされたポリスチレン樹脂、ポリジメチルアクリルアミ ド樹脂および多糖類より成る群から選ばれる、請求項1に記載の固相担体。 7.ハンドルをさらに含む、請求項1に記載の固相担体。 8.ハンドルが置換ベンズヒドリルアミンである、請求項7に記載の固相担体。 9.酸感受性、塩基感受性、求核試薬感受性、求電子試薬感受性、光感受性、酸 化感受性または還元感受性である第2のリンカーをさらに含む、請求項1に記載 の固相担体。 10.ONb、Glu-Pro ジペプチド、Asp-Pro ジペプチド、ヒドロキシメチル安息香 酸、ヒドロキシ酢酸、およびC末端のアミノ酸残基 がエステル結合で固相担体に共有結合されかつN末端のα−アミノ基が求核試薬 として作用するジペプチドより成る群から選ばれる第2のリンカーをさらに含む 、請求項1に記載の固相担体。 11.固相担体に結合されていないリンカーの酢酸基のカルボキシルがアルコール とエステル結合を形成する、請求項1に記載の固相担体。 12.アルコールがアミノ酸またはペプチドにアミド結合で結合されるアミノアル コールである、請求項11に記載の固相担体。 13.カルボン酸アームの1つのカルボキシル基と固相担体に結合されたイミノジ 酢酸分子のイミノ基との間のアミド結合により結合された第2のイミノジ酢酸分 子をさらに含む、請求項1に記載の固相担体。 14.イミノジ酢酸分子のイミノ基がアミノ酸のα−カルボキシルに結合される、 請求項1に記載の固相担体。 15.アミノ酸がグリシンである、請求項14に記載の固相担体。 16.第2のイミノジ酢酸分子のイミノ基がアミノ酸のα−カルボキシル基に結合 される、請求項13に記載の固相担体。 17.アミノ酸がグリシンである、請求項16に記載の固相担体。 18.固相担体に結合されていないイミノジ酢酸リンカーの酢酸基のカルボキシル がアミノ酸のα−アミノ基とアミドを形成し、該アミノ酸のα−カルボキシルが アルコールとエステル結合を形成する、請求項1に記載の固相担体。 19.アルコールがアミノ酸またはペプチドにアミド結合で結合されるアミノアル コールである、請求項18に記載の固相担体。 20.アミノ酸がプロリンである、請求項18に記載の固相担体。 21.リンカーが結合されており、該リンカーが第1の開裂可能な結合で結合され た第1の試験化合物と第2の開裂可能な結合で結合された第2の試験化合物を有 し、それぞれの結合の開裂がそれぞれの結合された試験化合物を放出し、第1の 結合がpH 8.5で不安定であって、第2の結合がpH 8.5で安定である、請求項1に 記載の固相担体。 22.第2の結合が0.1%水酸化ナトリウム中で開裂可能である、請求項21に記載 の固相担体。 23.リンカーが第2部分にエステル結合で結合された第1部分を含み、求核性基 とエステルがそれらの間の化学反応により複素環を形成するように配置されてお り、それにより第1の開裂可能な結合で結合された試験化合物が固相担体および 該複素環から放出される、請求項22に記載の固相担体。 24.複素環がジケトピペラジンである、請求項23に記載の固相担体。 25.複素環がヘキサヒドロピロロ(1,2-a)ピラジン-1,4-ジオンである、請求項23 に記載の固相担体。 26.第2部分は、第2エステル結合のカルボニルが試験化合物の一部となるよう に配置された第2エステル結合を含む、請求項23に記載の固相担体。 27.第2の開裂可能な結合は、エステル結合のカルボニルが試験化合物の一部と なるように配置されたエステル結合を含む、請求項23に記載の固相担体。 28.ペプチド結合で連結されたメチオニルを含む第1の開裂可能な結合およびエ ステルを含む第2の開裂可能な結合を有する固相合成に適するタイプの固相担体 。 29.N−保護イミノジアセチル部分を含む第1部分を有するリンカーを含んでな る、試験化合物の固相合成に適するタイプの固相担体であって、第1部分が第2 部分にエステル結合で結合しており、その際、イミノジアセチルおよびエステル 結合は、該エステルと脱保護イミンの間の求核化学反応がジケトピペラジン部分 を形成するように配置されており、それにより第2部分が固相担体およびジケト ピペラジンから開裂される、上記の固相担体。 30.Nα−保護グリシルイミノジアセチル基を含む第1部分を有するリンカーを 含んでなる、試験化合物の固相合成に適するタイプの固相担体であって、第1部 分が第2部分にエステル結合で結合されており、その際、グリシルイミノジアセ チルおよびエステル結合は、該エステルと脱保護アミンの間の求核反応がジケト ピペラジン部分を形成するように配置されており、それにより第2部分が固相担 体およびジケトピペラジンから開裂される、上記の固相担体。 31.請求項1の固相担体からペプチドを開裂する方法であって、ペプチドを6よ り高いpHの溶液にエステル結合を開裂するのに十分な時間さらすことを含んで なる、上記の方法。 32.請求項2の固相担体からペプチドを開裂する方法であって、 a.求核性基を脱保護し、そして b.ペプチドを7より高いpHの溶液にエステル結合を開裂するのに十分な 時間さらす、 各工程を含んでなる、上記の方法。 33.リンカーを構築し、そして合成された試験化合物を固相担体から開裂する方 法であって、 a.固相担体を第1のN−保護イミノジ酢酸でアシル化し、 b.第1のN−保護基を除去して、イミノ部分を第2のN−保護イミノジ酢 酸でアシル化し、 c.第1のイミノジ酢酸にエステル化されたアミノアルコールを介して固相 担体に結合された試験化合物を合成し、 d.第2のN−保護基を除去し、そして e.エステル化されたアミノアルコールがイミノ分解されるように固相担体 を維持する、 各工程を含んでなる、上記の方法。 34.リンカーを構築し、そして合成された試験化合物を固相担体から開裂する方 法であって、 a.固相担体をNα−保護グリシルイミノジ酢酸でアシル化し、 b.グリシルイミノジ酢酸にエステル化されたアミノアルコールを介して固 相担体に結合された試験化合物を合成し、 c.Nα−保護基を除去し、そして d.エステル化されたアミノアルコールがアミノ分解されるように固相担体 を維持する、 各工程を含んでなる、上記の方法。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8038893A | 1993-06-21 | 1993-06-21 | |
| US080,388 | 1993-06-21 | ||
| US8199793A | 1993-06-23 | 1993-06-23 | |
| US081,997 | 1993-06-23 | ||
| PCT/US1994/007012 WO1995000165A1 (en) | 1993-06-21 | 1994-06-21 | Selectively cleavable linkers based on iminodiacetic acid ester bonds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003159838A Division JP3672558B2 (ja) | 1993-06-21 | 2003-06-04 | イミノジ酢酸エステル結合に基づく選択的に開裂可能なリンカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH09500111A true JPH09500111A (ja) | 1997-01-07 |
| JP3469579B2 JP3469579B2 (ja) | 2003-11-25 |
Family
ID=26763448
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50304795A Expired - Fee Related JP3469579B2 (ja) | 1993-06-21 | 1994-06-21 | イミノジ酢酸エステル結合に基づく選択的に開裂可能なリンカー |
| JP2003159838A Expired - Fee Related JP3672558B2 (ja) | 1993-06-21 | 2003-06-04 | イミノジ酢酸エステル結合に基づく選択的に開裂可能なリンカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003159838A Expired - Fee Related JP3672558B2 (ja) | 1993-06-21 | 2003-06-04 | イミノジ酢酸エステル結合に基づく選択的に開裂可能なリンカー |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5635598A (ja) |
| EP (2) | EP0751779B1 (ja) |
| JP (2) | JP3469579B2 (ja) |
| AT (2) | ATE210993T1 (ja) |
| AU (1) | AU689116B2 (ja) |
| DE (2) | DE69429542T2 (ja) |
| DK (2) | DK1156059T3 (ja) |
| ES (2) | ES2165880T3 (ja) |
| NZ (1) | NZ268292A (ja) |
| PT (2) | PT1156059E (ja) |
| WO (1) | WO1995000165A1 (ja) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US5463564A (en) | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
| EP0774464B1 (en) * | 1995-10-17 | 2004-07-28 | Combichem, Inc. | A template for solution phase synthesis of combinatorial libraries |
| ES2213823T3 (es) * | 1996-04-08 | 2004-09-01 | Glaxo Group Limited | Codificacion y analisis cualitativo de bibliotecas combinatorias basadas en masa. |
| DE19626762A1 (de) * | 1996-07-03 | 1998-01-08 | Basf Ag | Enzymatisch spaltbare Linker für Festphasensynthesen |
| US6453246B1 (en) | 1996-11-04 | 2002-09-17 | 3-Dimensional Pharmaceuticals, Inc. | System, method, and computer program product for representing proximity data in a multi-dimensional space |
| US6295514B1 (en) | 1996-11-04 | 2001-09-25 | 3-Dimensional Pharmaceuticals, Inc. | Method, system, and computer program product for representing similarity/dissimilarity between chemical compounds |
| US6571227B1 (en) | 1996-11-04 | 2003-05-27 | 3-Dimensional Pharmaceuticals, Inc. | Method, system and computer program product for non-linear mapping of multi-dimensional data |
| DE69735112T2 (de) | 1996-11-06 | 2006-09-07 | Sequenom, Inc., San Diego | Verfahren zur Analyse und Vorrichtung |
| US6133436A (en) | 1996-11-06 | 2000-10-17 | Sequenom, Inc. | Beads bound to a solid support and to nucleic acids |
| EP1164203B1 (en) | 1996-11-06 | 2007-10-10 | Sequenom, Inc. | DNA Diagnostics based on mass spectrometry |
| US5958703A (en) * | 1996-12-03 | 1999-09-28 | Glaxo Group Limited | Use of modified tethers in screening compound libraries |
| US6168913B1 (en) * | 1997-10-14 | 2001-01-02 | Abbott Laboratories | Coding combinatorial libraries with fluorine tags |
| AU1589099A (en) * | 1997-11-18 | 1999-06-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Functionalized resin for the synthesis of amides and peptides |
| CA2260472A1 (en) * | 1998-02-11 | 1999-08-11 | Xiao-Yi Xiao | Safety-catch linkers |
| US7094943B2 (en) | 1998-04-27 | 2006-08-22 | Hubert Köster | Solution phase biopolymer synthesis |
| GB9912911D0 (en) * | 1999-06-04 | 1999-08-04 | Zeneca Ltd | Chemical process |
| US6309889B1 (en) | 1999-12-23 | 2001-10-30 | Glaxo Wellcome Inc. | Nano-grid micro reactor and methods |
| US7416524B1 (en) | 2000-02-18 | 2008-08-26 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | System, method and computer program product for fast and efficient searching of large chemical libraries |
| WO2001062772A2 (en) * | 2000-02-23 | 2001-08-30 | Xenoport, Inc. | Self-encoded combinatorial synthesis of compound multiplets |
| US6671627B2 (en) | 2000-02-29 | 2003-12-30 | 3-D Pharmaceuticals, Inc. | Method and computer program product for designing combinatorial arrays |
| US7039621B2 (en) | 2000-03-22 | 2006-05-02 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | System, method, and computer program product for representing object relationships in a multidimensional space |
| AU2001249805A1 (en) | 2000-04-03 | 2001-10-15 | 3-Dimensional Pharmaceuticals, Inc. | Method, system, and computer program product for representing object relationships in a multidimensional space |
| CA2419600A1 (en) * | 2000-08-22 | 2002-02-28 | 3-Dimensional Pharmaceuticals, Inc. | Method, system, and computer program product for determining properties of combinatorial library products from features of library building blocks |
| US6678619B2 (en) * | 2000-09-20 | 2004-01-13 | Victor S. Lobanov | Method, system, and computer program product for encoding and building products of a virtual combinatorial library |
| WO2002061419A1 (en) * | 2001-01-29 | 2002-08-08 | 3-Dimensional Pharmaceuticals, Inc. | Method, system, and computer program product for analyzing combinatorial libraries |
| US7262269B2 (en) * | 2001-10-26 | 2007-08-28 | The Regents Of University Of California | Method for screening combinational bead library; ligands for cancer cells |
| US6670142B2 (en) | 2001-10-26 | 2003-12-30 | The Regents Of The University Of California | Method for screening combinatorial bead library, capturing cells from body fluids, and ligands for cancer cells |
| US7291456B2 (en) | 2002-01-24 | 2007-11-06 | The Regents Of The University Of California | Method for determining differences in molecular interactions and for screening a combinatorial library |
| US20040185499A1 (en) * | 2003-03-20 | 2004-09-23 | Jolley Michael E. | Method of epitope scanning using fluorescence polarization |
| JP5107716B2 (ja) | 2004-11-05 | 2012-12-26 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | 分子治療用生分解性リンカー |
| EP2592103A1 (en) | 2011-11-08 | 2013-05-15 | Adriacell S.p.A. | Polymer aldehyde derivatives |
| CN103788367B (zh) * | 2014-02-26 | 2017-01-11 | 中国科学院长春应用化学研究所 | 一种聚酯酰胺及其制备方法 |
| JP2018503830A (ja) * | 2015-02-02 | 2018-02-08 | ツー ポア ガイズ インコーポレイテッド | バイオマーカー検出のための不安定なリンカー |
| ES2965764T3 (es) * | 2015-02-24 | 2024-04-16 | Hope City | Plataformas de cribado de bibliotecas abordadas espacialmente codificadas químicamente |
| DE102015117567B4 (de) | 2015-10-15 | 2017-05-11 | Stochastic Combinatorics GbR (vertretungsberechtigter Gesellschafter: Dr. Alexander Nesterov-Müller, 76661 Philippsburg) | Ultra-hochdichte Oligomerarrays und Verfahren zu deren Herstellung |
| IL283725B2 (en) | 2017-06-20 | 2024-04-01 | Imbria Pharmaceuticals Inc | Compositions and methods for increasing efficiency of cardiac metabolism |
| EP3866794B1 (en) | 2018-10-17 | 2024-12-04 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| EP3976101A4 (en) | 2019-05-31 | 2023-06-21 | Imbria Pharmaceuticals, Inc. | FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION |
| EP4057830A4 (en) * | 2019-11-14 | 2023-09-13 | BCD Bioscience, Inc. | HIGH YIELD PEROXIDE QUENCH CONTROLLED POLYSACCHARIDE DEPOLYMERIZATION AND COMPOSITIONS THEREOF |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
| WO2023102255A1 (en) * | 2021-12-03 | 2023-06-08 | Massachusetts Institute Of Technology | Peptide-encoded libraries of small molecules for de novo drug discovery |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3963701A (en) * | 1972-04-17 | 1976-06-15 | Richardson-Merrell Inc. | Substituted benzhydryl lactamimide derivatives |
| FR2595695B1 (fr) * | 1986-03-12 | 1988-12-02 | Synthelabo | Derives de n-(((hydroxy-2 phenyl) (phenyl) methylene) amino-2) ethyl) acetamide, leur preparation et leur application en therapeutique |
| ES2003862A4 (es) * | 1986-12-24 | 1988-12-01 | Monsanto Co | Resina soporte para la sintesis de peptidos en fase solida. |
| EP0322348B1 (de) * | 1987-12-22 | 1994-02-02 | Hoechst Aktiengesellschaft | Säurelabile Ankergruppen zur Synthese von Peptidamiden mittels Festphasenmethode |
| JP2815362B2 (ja) * | 1988-02-29 | 1998-10-27 | 中外製薬株式会社 | ベンズヒドリルアミン誘導体及びその製法 |
| US5066716A (en) * | 1988-12-13 | 1991-11-19 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Synthesis of chloroacetyl and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides |
| ATE123780T1 (de) * | 1989-02-17 | 1995-06-15 | Chiron Mimotopes Pty Ltd | Verfahren zur verwendung und herstellung von peptiden. |
| US5650489A (en) * | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| NL9002611A (nl) * | 1990-11-29 | 1992-06-16 | Crown Gear Bv | Gereedschap voor het vervaardigen van kroonwielen, alsmede werkwijze voor het vervaardigen van een dergelijk gereedschap. |
| CS103091A3 (en) * | 1991-04-12 | 1992-10-14 | Ustav Organicke Chemie A Bioch | Protected substituted benzhydrylamines as shoulders for the synthesis ofpeptides on solid phase, process of their preparation and use |
-
1994
- 1994-06-21 PT PT01114395T patent/PT1156059E/pt unknown
- 1994-06-21 DK DK01114395T patent/DK1156059T3/da active
- 1994-06-21 JP JP50304795A patent/JP3469579B2/ja not_active Expired - Fee Related
- 1994-06-21 WO PCT/US1994/007012 patent/WO1995000165A1/en not_active Ceased
- 1994-06-21 DE DE69429542T patent/DE69429542T2/de not_active Expired - Lifetime
- 1994-06-21 DE DE69435011T patent/DE69435011T2/de not_active Expired - Lifetime
- 1994-06-21 US US08/263,289 patent/US5635598A/en not_active Expired - Lifetime
- 1994-06-21 ES ES94920294T patent/ES2165880T3/es not_active Expired - Lifetime
- 1994-06-21 EP EP94920294A patent/EP0751779B1/en not_active Expired - Lifetime
- 1994-06-21 DK DK94920294T patent/DK0751779T3/da active
- 1994-06-21 NZ NZ268292A patent/NZ268292A/en not_active IP Right Cessation
- 1994-06-21 PT PT94920294T patent/PT751779E/pt unknown
- 1994-06-21 AT AT94920294T patent/ATE210993T1/de active
- 1994-06-21 AU AU71145/94A patent/AU689116B2/en not_active Ceased
- 1994-06-21 ES ES01114395T patent/ES2291245T3/es not_active Expired - Lifetime
- 1994-06-21 AT AT01114395T patent/ATE369376T1/de active
- 1994-06-21 EP EP01114395A patent/EP1156059B1/en not_active Expired - Lifetime
-
2003
- 2003-06-04 JP JP2003159838A patent/JP3672558B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0751779A1 (en) | 1997-01-08 |
| ATE210993T1 (de) | 2002-01-15 |
| ES2291245T3 (es) | 2008-03-01 |
| EP0751779A4 (en) | 1998-12-09 |
| EP1156059A1 (en) | 2001-11-21 |
| WO1995000165A1 (en) | 1995-01-05 |
| PT751779E (pt) | 2002-05-31 |
| DE69429542D1 (de) | 2002-01-31 |
| PT1156059E (pt) | 2007-10-19 |
| ATE369376T1 (de) | 2007-08-15 |
| US5635598A (en) | 1997-06-03 |
| JP2003327597A (ja) | 2003-11-19 |
| JP3672558B2 (ja) | 2005-07-20 |
| DE69429542T2 (de) | 2002-08-08 |
| DK0751779T3 (da) | 2002-04-15 |
| ES2165880T3 (es) | 2002-04-01 |
| JP3469579B2 (ja) | 2003-11-25 |
| DE69435011D1 (de) | 2007-09-20 |
| AU7114594A (en) | 1995-01-17 |
| EP0751779B1 (en) | 2001-12-19 |
| EP1156059B1 (en) | 2007-08-08 |
| NZ268292A (en) | 1997-09-22 |
| DK1156059T3 (da) | 2007-11-12 |
| AU689116B2 (en) | 1998-03-26 |
| DE69435011T2 (de) | 2008-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3469579B2 (ja) | イミノジ酢酸エステル結合に基づく選択的に開裂可能なリンカー | |
| US7589170B1 (en) | Synthesis of cyclic peptides | |
| US5795958A (en) | Library of glyco-peptides useful for identification of cell adhesion inhibitors | |
| Maeji et al. | Multi-pin peptide synthesis strategy for T cell determinant analysis | |
| US5965695A (en) | Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such | |
| Kruijtzer et al. | Solid‐phase syntheses of peptoids using Fmoc‐protected N‐substituted glycines: The synthesis of (retro) peptoids of Leu‐enkephalin and substance P | |
| EP0535155B1 (en) | Libraries of modified peptides with protease resistance | |
| Owens et al. | The rapid identification of HIV protease inhibitors through the synthesis and screening of defined peptide mixtures | |
| JPH09501490A (ja) | 位相学的に分離された、コードされた固相ライブラリー | |
| CA2301687A1 (en) | Phenethylamine derivatives | |
| US5422426A (en) | Rapid synthesis and screening of peptide mimetics | |
| SK287880B6 (sk) | Peptide LHRH-antagonists with improved solubility, pharmaceutical composition containing the peptides, method for the preparation of the peptides and their use and method for producing medicaments | |
| US4518527A (en) | Polypeptides related to the pre-acetylcholine receptor-α of the electric organ of Torpedo californica | |
| EP0804460A1 (en) | Conformationally constrained reverse-turn library and methods relating thereto | |
| CA2165780C (en) | Selectively cleavable linkers based on iminodiacetic acid ester bonds | |
| CA2579631C (en) | Selectively cleavable linkers based on iminodiacetic acid ester bonds | |
| WO1999031124A1 (en) | Cholic acid-based scaffolds for multidimensional molecular presentation of peptides | |
| JPS59219259A (ja) | ゴナドリベリン誘導体 | |
| Van Nispen et al. | Synthesis and charge‐transfer properties of two ACTH analogues containing pentamethylphenylalanine in position 9 | |
| JPH10501818A (ja) | 鋳型指向性環化 | |
| Stefanowicz | Direct solid-phase synthesis of quinoxaline-containing peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080905 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080905 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090905 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090905 Year of fee payment: 6 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090905 Year of fee payment: 6 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090905 Year of fee payment: 6 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090905 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100905 Year of fee payment: 7 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100905 Year of fee payment: 7 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100905 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110905 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120905 Year of fee payment: 9 |
|
| LAPS | Cancellation because of no payment of annual fees |